Company news

Patrys Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

GMP Production of PAT-DX1 Next Quarter

December 12, 2023

Appendix 4C - Quarterly - 30 September 2023

October 19, 2023

Appendix 4E and 2023 Annual Report

August 28, 2023

Appendix 4C - Quarterly - 30 June 2023

July 25, 2023

PAT-DX1 GLP toxicology reports received

May 23, 2023

Appendix 4C - Quarterly - 31 March 2023

April 24, 2023

Patrys secures US patents for antibody technology

April 17, 2023

Two new deoxymab patents granted in the USA

April 16, 2023

Updated guidance for PAT-DX1 phase 1 clinical study

March 30, 2023

New PAT-DX3 data demonstrates synthetic lethality

March 13, 2023

Appendix 4D - Half Year Accounts - 31 December 2022

February 24, 2023

Appendix 4C - Quarterly - 31 December 2022

January 30, 2023

Response to ASX Price Query

December 14, 2022

Patrys Appoints Global Biotechnology Leader as Chairman - In Preparation for First Clinical Trial for Groundbreaking Cancer Therapy

November 18, 2022

Appendix 4C - Quarterly - 30 September 2022

October 27, 2022

PAT DX3 Crosses Blood Brain Barrier in Healthy Animals

October 16, 2022

Appendix 4E and 2022 Annual Report

August 30, 2022

PAT-DX1 From Engineering Run Meets all Specification Tests

August 29, 2022

New Research Grant For Deoxymabs in Metastatic Breast Cancer

August 26, 2022

PAT-DX1/Radiation Combination Improves Brain Cancer Survival

August 9, 2022

Appendix 4C - Quarterly - 30 June 2022

July 27, 2022

PAT-DX1 Engineering Run Successfully Completed

July 3, 2022

New Mechanism By Which PAT-DX1 May Reduce Cancer Metastasis

June 13, 2022

CBCF funding to support deoxymab brain cancer development

June 3, 2022

Appendix 4C - Quarterly - 31 March 2022

April 28, 2022

Application for quotation of securities - PAB

April 14, 2022

Stable Cell Line for Production of PAT-DX3 Established

February 27, 2022

Appendix 4D - Half Year Accounts - 31 December 2021

February 24, 2022

Appendix 4C - Quarterly - 31 December 2021

January 30, 2022

PAT-DX1 engineering update

January 23, 2022

Ceasing to be a substantial holder from MQG

December 8, 2021

Change of Director's Interest Notices x2

December 6, 2021

Rights Issue Results and Shortfall Notification

December 2, 2021

Notification regarding unquoted securities - PAB

November 22, 2021

Rights Issue Offer Document

November 8, 2021

$7.8M Capital Raising

October 31, 2021

Appendix 4C - Quarterly - 30 September 2021

October 19, 2021

Patrys proof of concept ADC significantly increases survival

October 17, 2021

PAT-DX3 proof of concept as potential ADC targeting antibody

September 14, 2021

Appendix 4E and 2021 Annual Report

August 25, 2021

Market Update - PAT-DX1 Clinical Trial Preparation

August 2, 2021

Appendix 4C - Quarterly - 30 June 2021

July 29, 2021

PAT-DX1 Improves Survival in Model of Pancreatic Cancer

July 25, 2021

Full size deoxymab PAT-DX3 crosses the blood brain barrier

July 11, 2021

Response to ASX Query

June 23, 2021

Patrys Limited Announces Publication of PAT-DX1 Preclinical Data in JCI - Insight

June 16, 2021

Paper highlights PAT-DX1 as potential brain cancer treatment

June 15, 2021

Patrys receives R&D Tax Incentive refund

June 9, 2021

Appendix 4C - Quarterly - 31 March 2021

April 27, 2021

New United States patent granted for Patrys deoxymab assets

March 30, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 43 decks. Every deck is listed under its year.